Paul C - Search Results

1

Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells.

Rhedin AS, Tidefelt U, Jönsson K, Lundin A, Paul C. Rhedin AS, et al. Among authors: paul c. Leuk Res. 1993 Mar;17(3):271-6. doi: 10.1016/0145-2126(93)90011-9. Leuk Res. 1993. PMID: 7680736

2

In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia.

Möllgård L, Prenkert M, Smolowicz A, Paul C, Tidefelt U. Möllgård L, et al. Among authors: paul c. Leuk Lymphoma. 2003 May;44(5):783-9. doi: 10.1080/1042819031000067594. Leuk Lymphoma. 2003. PMID: 12802914

3

The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60).

Segura-Aguilar J, Jönsson K, Tidefelt U, Paul C. Segura-Aguilar J, et al. Among authors: paul c. Leuk Res. 1992 Jun-Jul;16(6-7):631-7. doi: 10.1016/0145-2126(92)90013-w. Leuk Res. 1992. PMID: 1635381

4

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852

5

Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C. Sundman-Engberg B, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1990;25(4):252-6. doi: 10.1007/BF00684881. Cancer Chemother Pharmacol. 1990. PMID: 2295112

6

In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.

Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. Tidefelt U, et al. Among authors: paul c. Eur J Haematol. 1989 Nov;43(5):374-84. doi: 10.1111/j.1600-0609.1989.tb00323.x. Eur J Haematol. 1989. PMID: 2482193 Clinical Trial.

7

Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.

Paul C, Tidefelt U, Liliemark J, Peterson C. Paul C, et al. Leuk Res. 1989;13(2):191-6. doi: 10.1016/0145-2126(89)90145-8. Leuk Res. 1989. PMID: 2927175

8

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.

Gruber A, Liliemark E, Tidefelt U, Paul C, Björkholm M, Peterson C, Liliemark J. Gruber A, et al. Among authors: paul c. Leuk Res. 1995 Oct;19(10):757-61. doi: 10.1016/0145-2126(95)00061-r. Leuk Res. 1995. PMID: 7500654

9

Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Leuk Res. 1994 Apr;18(4):293-7. doi: 10.1016/0145-2126(94)90032-9. Leuk Res. 1994. PMID: 8170171

10

Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Gruber A, Paul C. Sundman-Engberg B, et al. Among authors: paul c. Leuk Res. 1993 Apr;17(4):347-52. doi: 10.1016/0145-2126(93)90022-d. Leuk Res. 1993. PMID: 8487583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,216 results

Search Page

Filters